Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats

被引:16
作者
Aviles-Rosas, V. H. [1 ]
Rivera-Mancilla, E. [1 ]
Marichal-Cancino, B. A. [1 ]
Manrique-Maldonado, G. [1 ]
Altamirano-Espinoza, A. H. [1 ]
Van den Brink, A. Maassen [2 ]
Villalon, C. M. [1 ]
机构
[1] Cinvestav Coapa, Dept Farmacobiol, Tenorios 235, Mexico City 14330, DF, Mexico
[2] Univ Med Ctr Rotterdam, Erasmus MC, Div Pharmacol Vasc & Metab Dis, Dept Internal Med, Rotterdam, Netherlands
关键词
GENE-RELATED PEPTIDE; RECEPTORS MEDIATING INHIBITION; PHARMACOLOGICAL PROFILE; ANTAGONIST BIBN4096BS; SUBSTANCE-P; CGRP; OUTFLOW; STIMULATION; PUBLICATION; MIGRAINE;
D O I
10.1111/bph.13799
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and PurposeOlcegepant (BIBN4096BS) is a selective non-peptide CGRP receptor antagonist with acute antimigraine properties. Since systemic vascular tone is modulated by perivascular (primary sensory CGRPergic and sympathetic) nerves, this randomized study investigated in pithed rats the effect of acute i.v. treatment with olcegepant on the neurogenic and non-neurogenic: (i) CGRPergic vasodepressor responses; and (ii) noradrenergic vasopressor responses. The pithed rat is an experimental model predictive of systemic (cardio) vascular side effects. Experimental ApproachSeventy-five male Wistar rats (divided into 15 groups, n=5 each) were pithed, artificially ventilated and prepared for: (i) spinal stimulation (T-9-T-12; 0.56-5.6Hz) of the sensory CGRPergic vasodepressor outflow or i.v. bolus injections (0.1-1gkg(-1)) of -CGRP, substance P or acetylcholine, which induced frequency-dependent or dose-dependent vasodepressor responses; or (ii) spinal stimulation (T-7-T-9; 0.03-3Hz) of the sympathetic vasopressor outflow or i.v. bolus injections (0.03-3gkg(-1)) of noradrenaline, which produced frequency-dependent or dose-dependent vasopressor responses. Key ResultsOlcegepant (1000 and 3000gkg(-1), i.v.) dose-dependently blocked the vasodepressor responses to sensory nerve stimulation or i.v. -CGRP, without affecting those to substance P or acetylcholine. Whereas it potentiated the vasopressor responses to sympathetic nerve stimulation or i.v. noradrenaline. Conclusions and ImplicationsOlcegepant (i.v.) selectively blocked the neurogenic and non-neurogenic CGRPergic vasodepressor responses. This blockade by olcegepant potentiated the neurogenic and non-neurogenic noradrenergic vasopressor responses in pithed rats, an effect that might result in an increased vascular resistance and, consequently, in a prohypertensive action.
引用
收藏
页码:2001 / 2014
页数:14
相关论文
共 42 条
[1]   THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors [J].
Alexander, Stephen P. H. ;
Davenport, Anthony P. ;
Kelly, Eamonn ;
Marrion, Neil ;
Peters, John A. ;
Benson, Helen E. ;
Faccenda, Elena ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Southan, Christopher ;
Davies, Jamie A. ;
Aldrich, R. ;
Attali, B. ;
Back, M. ;
Barnes, N. M. ;
Bathgate, R. ;
Beart, P. M. ;
Becirovic, E. ;
Biel, M. ;
Birdsall, N. J. ;
Boison, D. ;
Brauner-Osborne, H. ;
Broeer, S. ;
Bryant, C. ;
Burnstock, G. ;
Burris, T. ;
Cain, D. ;
Calo, G. ;
Chan, S. L. ;
Chandy, K. G. ;
Chiang, N. ;
Christakos, S. ;
Christopoulos, A. ;
Chun, J. J. ;
Chung, J. -J. ;
Clapham, D. E. ;
Connor, M. A. ;
Coons, L. ;
Cox, H. M. ;
Dautzenberg, F. M. ;
Dent, G. ;
Douglas, S. D. ;
Dubocovich, M. L. ;
Edwards, D. P. ;
Farndale, R. ;
Fong, T. M. ;
Forrest, D. ;
Fowler, C. J. ;
Fuller, P. ;
Gainetdinov, R. R. .
BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (24) :5744-5869
[2]  
Arulmani U, 2004, BASIC CLIN PHARMACOL, V94, P291
[3]   Calcitonin gene-related peptide: Vasoactive effects and potential therapeutic role [J].
Brain, SD ;
Cambridge, H .
GENERAL PHARMACOLOGY, 1996, 27 (04) :607-611
[4]   SELECTIVE BLOCKADE BY NIFEDIPINE OF PURINERGIC RATHER THAN ADRENERGIC NERVE-MEDIATED VASOPRESSOR RESPONSES IN THE PITHED RAT [J].
BULLOCH, JM ;
MCGRATH, JC .
BRITISH JOURNAL OF PHARMACOLOGY, 1988, 95 (03) :695-700
[5]   Experimental design and analysis and their reporting: new guidance for publication in BJP [J].
Curtis, Michael J. ;
Bond, Richard A. ;
Spina, Domenico ;
Ahluwalia, Amrita ;
Alexander, Stephen P. A. ;
Giembycz, Mark A. ;
Gilchrist, Annette ;
Hoyer, Daniel ;
Insel, Paul A. ;
Izzo, Angelo A. ;
Lawrence, Andrew J. ;
MacEwan, David J. ;
Moon, Lawrence D. F. ;
Wonnacott, Sue ;
Weston, Arthur H. ;
McGrath, John C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (14) :3461-3471
[6]   RECIPROCAL SYMPATHO-SENSORY CONTROL: FUNCTIONAL ROLE OF NUCLEOTIDES AND CALCITONIN GENE-RELATED PEPTIDE IN A PERIPHERAL NEUROEFFECTOR JUNCTION [J].
Donoso, M. V. ;
Hermosilla, D. ;
Navarrete, C. ;
Alvarez, P. ;
Lillo, J. G. ;
Huidobro-Toro, J. P. .
NEUROSCIENCE, 2012, 203 :216-229
[7]   Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist [J].
Doods, H ;
Hallermayer, G ;
Wu, DM ;
Entzeroth, M ;
Rudolf, K ;
Engel, W ;
Eberlein, W .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (03) :420-423
[8]   CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment [J].
Edvinsson, Lars .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (02) :193-199
[9]   A METHOD OF STIMULATING DIFFERENT SEGMENTS OF AUTONOMIC OUTFLOW FROM SPINAL COLUMN TO VARIOUS ORGANS IN PITHED CAT AND RAT [J].
GILLESPIE, JS ;
MACLAREN, A ;
POLLOCK, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1970, 40 (02) :257-+
[10]   Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases [J].
Gonzalez-Hernandez, Abimael ;
Marichal-Cancino, Bruno A. ;
Lozano-Cuenca, Jair ;
Lopez-Canales, Jorge S. ;
Munoz-Islas, Enriqueta ;
Ramirez-Rosas, Martha B. ;
Villalon, Carlos M. .
BIOMED RESEARCH INTERNATIONAL, 2016, 2016